180 related articles for article (PubMed ID: 28462607)
1. Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study.
Buoli M; Esposito CM; Godio M; Caldiroli A; Serati M; Altamura AC
J Psychopharmacol; 2017 Dec; 31(12):1537-1543. PubMed ID: 28462607
[TBL] [Abstract][Full Text] [Related]
2. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
Bipolar Disord; 2009 Nov; 11(7):673-86. PubMed ID: 19839993
[TBL] [Abstract][Full Text] [Related]
3. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.
Chwieduk CM; Scott LJ
CNS Drugs; 2011 Mar; 25(3):251-67. PubMed ID: 21323396
[TBL] [Abstract][Full Text] [Related]
4. Asenapine versus olanzapine in acute mania: a double-blind extension study.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
Bipolar Disord; 2009 Dec; 11(8):815-26. PubMed ID: 19832806
[TBL] [Abstract][Full Text] [Related]
5. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
6. Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program.
Szegedi A; Zhao J; McIntyre RS
J Affect Disord; 2013 Sep; 150(3):745-52. PubMed ID: 23473546
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.
Mahajan V; Arora M; Tandon VR; Gillani Z; Praharaj SK
J Clin Psychopharmacol; 2019; 39(4):305-311. PubMed ID: 31205195
[TBL] [Abstract][Full Text] [Related]
8. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
J Affect Disord; 2010 Apr; 122(1-2):27-38. PubMed ID: 20096936
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study.
Katagiri H; Takita Y; Tohen M; Higuchi T; Kanba S; Takahashi M
J Affect Disord; 2012 Feb; 136(3):476-84. PubMed ID: 22134043
[TBL] [Abstract][Full Text] [Related]
10. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
J Affect Disord; 2010 Nov; 126(3):358-65. PubMed ID: 20537396
[TBL] [Abstract][Full Text] [Related]
11. A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania.
Moreno RA; Hanna MM; Tavares SM; Wang YP
Braz J Med Biol Res; 2007 Mar; 40(3):357-66. PubMed ID: 17334533
[TBL] [Abstract][Full Text] [Related]
12. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.
Azorin JM; Sapin C; Weiller E
J Affect Disord; 2013 Feb; 145(1):62-9. PubMed ID: 22868059
[TBL] [Abstract][Full Text] [Related]
13. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.
McIntyre RS; Tohen M; Berk M; Zhao J; Weiller E
J Affect Disord; 2013 Sep; 150(2):378-83. PubMed ID: 23712026
[TBL] [Abstract][Full Text] [Related]
14. Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder.
Landbloom RL; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
J Affect Disord; 2016 Jan; 190():103-110. PubMed ID: 26496015
[TBL] [Abstract][Full Text] [Related]
15. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.
Berk M; Tiller JW; Zhao J; Yatham LN; Malhi GS; Weiller E
J Clin Psychiatry; 2015 Jun; 76(6):728-34. PubMed ID: 25612216
[TBL] [Abstract][Full Text] [Related]
16. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Szegedi A; Calabrese JR; Stet L; Mackle M; Zhao J; Panagides J;
J Clin Psychopharmacol; 2012 Feb; 32(1):46-55. PubMed ID: 22198448
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.
Sawyer L; Azorin JM; Chang S; Rinciog C; Guiraud-Diawara A; Marre C; Hansen K
J Med Econ; 2014 Jul; 17(7):508-19. PubMed ID: 24720805
[TBL] [Abstract][Full Text] [Related]
18. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.
Suppes T; Brown E; Schuh LM; Baker RW; Tohen M
J Affect Disord; 2005 Dec; 89(1-3):69-77. PubMed ID: 16253344
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
Katagiri H; Takita Y; Tohen M; Higuchi T; Kanba S; Takahashi M
Curr Med Res Opin; 2012 May; 28(5):701-13. PubMed ID: 22356118
[TBL] [Abstract][Full Text] [Related]
20. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania.
Berk M; Ng F; Wang WV; Tohen M; Lubman DI; Vieta E; Dodd S
J Affect Disord; 2008 Sep; 110(1-2):126-34. PubMed ID: 18280579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
